FACULTY
Ikuo Hirano, MD
Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, IL
PROGRAM OVERVIEW
The RESTORE enduring will focus on the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE). Patients with EoE are often diagnosed after symptom onset, leading to greater chronic inflammation, and treatment plans are frequently not tailored to individual needs. This activity is intended to help healthcare professionals diagnose EoE earlier and provide individualized treatment based on guidelines, recent clinical data, and patient characteristics.
TARGET AUDIENCE
The RESTORE Initiative is intended to meet the educational needs of gastroenterologists, allergist/ immunologists, ENT specialists, and other members of the multidisciplinary team to ensure optimal patient outcomes in the management of EoE.
LEARNING OBJECTIVES
- Evaluate the underlying pathophysiology of eosinophilic esophagitis as related to the type 2 inflammatory pathway
- Examine deficiencies in existing off-label therapies for the management of eosinophilic esophagitis
- Summarize current clinical data concerning the use of novel therapies for the management of eosinophilic esophagitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Ikuo Hirano, MD discloses that he has served as a consultant for Regeneron/Sanofi, Allakos, Elodi/Adare, Takeda/Shire, Bristol Myers Squibb, Calyx, Parexel, AstraZeneca and Amgen. Dr. Hirano also conducted research for Regeneron/Sanofi. Allakos, Elodi/Adare, Takeda/Shire, Bristol Myers Squibb, AstraZeneca and Amgen.
All relevant financial relationships have been mitigated
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: November 29, 2022
EXPIRATION DATE: November 29, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
